Zdrowie i gospodarka · 13/05/2015
FDA Releases Draft Guidance for Investigational Enzyme Replacement Therapy Products
The FDA has made available a draft guidance document to help industry sponsors prepare nonclinical studies for enzyme replacement therapy products, aiming to support first-in-human clinical trials and eventual approval for rare, life-threatening conditions.
Source: Federal Register — Food and Drug AdministrationOpen original release →